Global Chronic Lymphocytic Leukemia market 2016-2020


#729302

78pages

Technavio

$ 2500

In Stock

About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
Acute myeloid (or myelogenous) leukemia (AML)
Chronic myeloid (or myelogenous) leukemia (CML)
Acute lymphocytic (or lymphoblastic) leukemia (ALL)
CLL

Technavios analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hoffman-La Roche
AbbVie
Teva Pharmaceuticals
Gilead Sciences
Novartis
Johnson & Johnson

Other prominent vendors
Altor BioScience
Amgen
Arno Therapeutics
AstraZeneca
Bellicum Pharmaceuticals
Biogen
BioLineRx
Boston Biomedical
Celgene
Emergent BioSolutions
Genzyme
iDD biotech
Immunomedics
Infinity Pharmaceuticals
Innate Pharma
Karyopharm Therapeutics
Ligand Pharmaceuticals
MedImmune
Merck Sharp & Dohme
Molecular Templates Inc.
MorphoSys
Ono Pharmaceutical
Portola Pharmaceuticals
Regeneron Pharmaceuticals
Sunesis Pharmaceuticals
TG Therapeutics
TheraMAB
XEME Biopharma
Xencor
ZIOPHARM Oncology

Market driver
Special regulatory designations
For a full, detailed list, view our report

Market challenge
High cost of therapy
For a full, detailed list, view our report

Market trend
Rise in development of combination therapies
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.